Related by context. All words. (Click for frequent words.) 72 BAL# [002] 72 Antitumor 71 Orally Active 70 Anti Tumor 69 Bosutinib 69 Granted Orphan Drug 69 Files IND 69 Xanafide 69 Phase 2b Clinical Trial 69 Vitro Activity 69 R Saizen R 69 Adjuvant Treatment 69 Recombinant Human 69 Hsp# Inhibitor 69 Meets Primary Endpoint 69 Daptomycin 68 vapreotide acetate 68 Prolongs Survival 68 Anti Tumor Activity 68 Drug Candidate 68 Completes Patient Enrollment 68 receptor tyrosine kinase inhibitor 68 somatostatin analog 68 Aurora Kinase 68 Pathway Inhibitor 68 Tyrosine Kinase Inhibitor 68 Zorbtive TM 68 Patients Treated With 68 Delafloxacin 68 Complicated Skin 68 topoisomerase II inhibitor 68 Immunomodulatory 68 Presents Preclinical Data 68 Parathyroid Hormone 68 Kinase Inhibitor 67 Fast Track Status 67 Novel Inhibitor 67 humanized monoclonal 67 Nucleoside 67 selective orally bioavailable 67 Soft Tissue Sarcoma 67 Darinaparsin 67 sunitinib Sutent ® 67 liposomal formulation 67 Receives Orphan Drug 67 Demonstrates Significant 67 AAG geldanamycin analog 67 Submits NDA 67 CYT# potent vascular disrupting 67 Liposomal 67 Receives Orphan Drug Designation 67 Systemic Delivery 67 Previously Treated 67 Trial Evaluating 67 ara C 67 Investigational Compound 67 Omacetaxine 67 orally administered inhibitor 66 Novel Oral 66 ALVESCO ® 66 Interferon alpha 66 Interferon alpha 2b 66 Granulocyte Colony Stimulating Factor 66 selective antagonist 66 Personalized Immunotherapy 66 Nilotinib 66 highly selective inhibitor 66 Epratuzumab 66 PEGylated Fab fragment 66 Maribavir 66 First Patient Dosed 66 ceftazidime 66 Tigecycline 66 Nitazoxanide 66 Attenuates 66 fosbretabulin 66 dasatinib Sprycel ® 66 TNF Tumor Necrosis Factor 66 Protease 66 beta 1a 66 hyaluronidase enzyme 66 Kahalalide F 66 Combination REOLYSIN R 66 pathophysiological effects 66 Alkaline Phosphatase 66 glycopeptide 66 Onconase 66 Phase 2b Trial 66 Mycophenolate Mofetil 66 Pivotal Phase III 66 alefacept 66 Peginterferon Alfa 2a 66 Pharmacokinetics PK 66 Safinamide 66 Advanced Renal Cell 65 itraconazole Sporanox 65 Placebo Controlled Trial 65 tumor xenograft models 65 MAGE A3 ASCI 65 Prospective Randomized 65 Mg Usa 65 Interferon alfa 65 Chemokine Receptor 65 novel emulsion formulation 65 Improves Outcomes 65 refractory chronic lymphocytic 65 Clinical Trial Results 65 thalidomide Thalomid 65 Melphalan 65 Presents Positive 65 tigecycline 65 Shows Promise Against 65 Budesonide 65 Interferon Beta 65 Shows Efficacy 65 Macrolide 65 PEG IFN 65 bactericidal activity 65 demonstrated antitumor activity 65 Fluconazole 65 imatinib Gleevec ® 65 Dasatinib 65 Commences Phase 65 Vidaza azacitidine 65 immune modulating 65 Ovitrelle R Serostim 65 Epidermal Growth Factor Receptor 65 Oral Fingolimod 65 LymphoStat B belimumab 65 Anidulafungin 65 GW# [003] 65 Phase III Clinical Trial 65 topical gel formulation 65 Antiviral Activity 65 NDA Submission 65 Cardiotoxicity 65 Cinacalcet HCl 65 Polymerase Inhibitor 65 vinca alkaloid 65 Hypertensive Patients 65 Cathepsin S 65 Teva Provides Update 65 developing Bicifadine serotonin 65 Commence Phase 65 calcipotriene 65 Kuvan sapropterin dihydrochloride 65 arsenic trioxide injection 65 FDA Accepts 65 Gonal f ® 65 monoclonal antibody conjugated 65 Aptamer 65 Antitumor Activity 65 Tezampanel 65 Patent Covering 65 Initiate Phase 65 Xeloda ® 65 Initiates Phase II 65 Improves Survival 65 Vinorelbine 65 RNAi Therapeutic 65 bevacizumab Avastin R 65 histone deacetylase HDAC inhibitor 65 chimeric monoclonal antibody 65 Itraconazole 65 HuMax 65 JAK Inhibitor 65 Initiates Clinical Trials 65 CYP#A# CYP#D# 65 Pivotal Study 65 Preclinical Data 64 Shows Promising 64 IMiDs ® 64 ENMD # 64 Single Dose 64 Pegylated 64 COPEGUS R 64 evaluating tivozanib 64 Long Term Efficacy 64 targeted antifolate 64 Intravenous Human 64 Immunotherapeutic 64 IND Application 64 Investigational Oral 64 Lenalidomide 64 fluoroquinolone antibiotic 64 immune stimulatory 64 Belerofon 64 Initiates Enrollment 64 essential thrombocythemia ET 64 novel histone deacetylase 64 Myeloid 64 Receives Approvable Letter 64 Interferon Gamma 64 Antiangiogenic 64 Phase Ib Clinical Trial 64 Pooled Analysis 64 Phase IIb Clinical Trial 64 Pruvel TM 64 Demonstrates Positive 64 lenalidomide Revlimid ® 64 Pemetrexed 64 Sustained Release 64 Novel Antibiotic 64 Orally administered 64 Temsirolimus 64 Cytotoxic 64 Initiates Phase III 64 sodium glucose cotransporter 64 selective A2A adenosine receptor 64 TNF alpha selectively neutralizing 64 FUSILEV enhances 64 Pralatrexate 64 Preclinical Study 64 Small Molecule 64 mitogen activated ERK kinase 64 Vitrasert R 64 oral prodrug 64 Moxifloxacin 64 peptide conjugated 64 Immunogenicity 64 broad spectrum cephalosporin 64 Aliskiren 64 Inhibits 64 NS#/#A protease 64 Crofelemer budesonide foam 64 nilotinib Tasigna ® 64 oral picoplatin 64 novel VDA molecule 64 microtubule inhibitor 64 Study Evaluating 64 Receives Fast Track 64 Vidaza R 64 Plaque Psoriasis 64 Novel Compound 64 Oracea ® 64 Oncolytic 64 Degarelix 64 Gleevec resistant 64 Panzem R 64 Angiotensin Converting Enzyme 64 small molecule Hedgehog 64 MTP inhibitor 64 TO AVOID PREGNANCY WHILE 64 Initiates Clinical Trial 64 ARRY # 64 dopamine D2 64 Presents Preclinical 64 secretory phospholipase A2 64 Lymphocytic 64 Chronic Hepatitis C 64 ABLYNX 64 Thiovir 64 Factor Receptor 64 polyglutamate 64 benzimidazole 64 Monoclonal Antibody 64 Mg Uk 64 Diffuse Large B 64 Aflibercept 64 Linezolid 64 erlotinib Tarceva ® 64 Antithrombin 64 AnaSpec Introduces 64 CYP#A# substrate 64 Hormone Refractory Prostate Cancer 64 Bazedoxifene 64 Alfacell proprietary ribonuclease 64 Modulates 64 Posaconazole 64 Oral Insulin 64 Inflammatory Arthritis 64 UPLYSO 64 Tocilizumab 64 Adjuvant Chemotherapy 64 Metformin HCl 64 antagonist LAMA 64 Fibrinogen 64 Voreloxin 64 FDA Approvals 64 Demonstrates Efficacy 64 Phase IIb Trial 64 iobenguane 64 Adenoviral 64 ® lenalidomide 64 Vildagliptin 64 Completes Enrollment 63 Receptor Agonist 63 PEGylated interferon 63 FDA APPROVES 63 Medullary Thyroid Cancer 63 Hydrochlorothiazide Tablets 63 Anti CD# Antibody 63 ADP receptor antagonist 63 Glufosfamide 63 lexidronam injection 63 brand ciclesonide HFA 63 Combination Therapy 63 topical ophthalmic 63 beta lactamase inhibitor 63 Phase 2a Clinical Trial 63 Refractory Hodgkin Lymphoma 63 Severe Sepsis 63 Novel Therapeutic 63 RhuDex ® 63 candidates Azedra TM 63 acyclovir Lauriad R 63 Relapsed Refractory 63 Progenitor Cells 63 Protease Inhibitors 63 Confirms Efficacy 63 FDA Clearance 63 topically administered 63 NS5b 63 Squalamine 63 Analogues 63 novel orally bioavailable 63 Advanced Melanoma 63 Metastatic Colorectal Cancer 63 K. pneumoniae 63 Immune Responses 63 Cloretazine VNP#M 63 Bafetinib 63 Receives Marketing Authorization 63 selective adenosine 63 class anticancer quinolone 63 Relapsing Multiple Sclerosis 63 FDA Clears 63 Sevelamer 63 PROSTASCINT R 63 Sphingomab TM 63 Orphan Drug status 63 prucalopride 63 Vaccine Adjuvant 63 Conjugate 63 EGFR HER2 63 Prodrug 63 Fludara ® 63 vinorelbine tartrate 63 R lenalidomide 63 Lyophilized 63 Benazepril 63 II Clinical Trial 63 topically applied SEPA 63 Pafuramidine 63 5 HT2A inverse 63 relapsed MM 63 Smooth Muscle 63 accumulate preferentially 63 Interferon Alpha 63 Allogeneic 63 Central Venous Catheters 63 protein tyrosine phosphatase 1B 63 PEGylated anti 63 Diabetic Neuropathy 63 orally bioavailable 63 platform HDL Mimetic 63 synthetic peptide containing 63 apoptosis inducers 63 Aeolus Pharmaceuticals Announces 63 Transdermal Patch 63 Cyclophosphamide 63 Initiates Clinical 63 Plasmid DNA 63 Tesamorelin 63 PGL# 63 RhuDex R 63 GRAS Status 63 Ambrisentan 63 Peginterferon alfa 2b 63 herpes simplex viruses 63 SPL# Gel vaginal microbicide 63 Potent Anti 63 investigational oral inhibitor 63 Protease Inhibitor 63 selective adhesion molecule 63 docetaxel Taxotere ® 63 Significantly Improves 63 Archexin 63 Viprovex ® 63 Xcytrin R 63 selective modulator 63 Relapsing Remitting Multiple Sclerosis 63 Taxane 63 macrolide antibiotic 63 CDK inhibitor 63 SPRYCEL ® 63 Replacement Therapy 63 Crit Rev 63 sulfonamide 63 Investigational Treatment 63 SensoLyte ™ 63 Ziprasidone 63 Pivotal Phase 63 Potent Antiviral Activity 63 potent antiproliferative 63 ® bortezomib 63 Antigen Specific 63 Monotherapy 63 mediated inhibition 63 administered concomitantly 63 Pazopanib 63 Nasal Spray 63 Albuferon TM 63 formerly LymphoStat B 63 Ganciclovir 63 Vaccine Adjuvants 63 HDAC Inhibitor 63 PI3K/mTOR 63 Retinoic Acid 63 Capecitabine 63 lead molecular radiotherapeutic 63 NS5B polymerase 63 DNA intercalator 63 replicon 63 proprietary polysaccharide 63 Fulvestrant 62 Monoclonal 62 Intravesical 62 Initiate Clinical Trial 62 Respiratory Virus 62 Interferons 62 Ceflatonin 62 Peginterferon 62 Mouse Model 62 NeutroPhase TM 62 Atopic Dermatitis 62 Doripenem 62 Biolimus A9 62 Drug Resistant 62 By JENNIFER LEARN 62 Inhaled Corticosteroids 62 Antibacterials 62 non peptidic protease 62 Silodosin 62 Wound Dressing 62 Controlled Trial 62 inhalation powder 62 DNA methyltransferase inhibitors 62 Dehydrogenase 62 MetroGel 62 5 FU leucovorin 62 Selective Inhibitor 62 Inhalation Aerosol 62 potently inhibit 62 Submits IND 62 Tumor Targeting 62 Bortezomib 62 Pegylated Liposomal Doxorubicin 62 Significantly Improved 62 Cethromycin 62 #mg/#mg 62 Gemcitabine 62 ergot derivatives 62 Carfilzomib 62 Interferon beta 62 potent anti angiogenic 62 Zysolin TM 62 ATRA IV 62 Disease Modifying 62 Present Preclinical Data 62 Proc Am Soc 62 Recombinant Protein 62 plus prednisone prednisolone 62 Panzem NCD 62 Lanthanum Carbonate 62 Humanized Anti 62 Study Demonstrates 62 Grants Orphan Drug 62 Clindamycin 62 IAP inhibitor 62 selective kinase inhibitor 62 Hepatocellular 62 Drug Shows Promise 62 Announcement acc 62 Vidaza ® 62 p# alpha [001] 62 HCV Protease Inhibitor 62 Successfully Completes Phase 62 Randomized Double Blind 62 Neovascularization 62 fluconazole resistant 62 radezolid 62 Fluticasone 62 preclinical efficacy 62 treat chronic sinusitis 62 Phase 2a Trial 62 Metastatic Melanoma 62 Files Investigational 62 Announces Tentative Approval 62 Corynebacterium 62 Valortim TM 62 pan HDAC inhibitor 62 Haemophilus b Conjugate 62 dihydrochloride 62 SYN# 62 Pivotal Phase II 62 Receives FDA Clearance 62 PNP inhibitor 62 Alferon N 62 myelodysplastic myeloproliferative diseases 62 T#I [002] 62 MKC# MT 62 PROVENGE ® 62 Microspheres 62 Subunit 62 Darunavir 62 Clinical Trial Evaluating 62 abacavir sulfate lamivudine 62 solithromycin 62 agonistic human 62 Confirmatory Phase 62 kidney urologic 62 Tolvaptan 62 meropenem 62 liposome formulation 62 pharmacokinetic PK study 62 Bacteremia 62 GMX# 62 Demonstrates Potent 62 Zalypsis 62 lenalidomide Revlimid R 62 Anti Inflammatory 62 Maleate 62 humanised monoclonal antibody 62 Fludarabine 62 Human Monoclonal Antibody 62 Well Tolerated 62 CD# CD# 62 non nucleoside inhibitor 62 PRTX 62 soluble tumor necrosis 62 ZEVALIN ® 62 Induces Apoptosis 62 Polymorphisms 62 Efficacy Trial 62 hypereosinophilic syndrome 62 FEMALES SHOULD BE ADVISED 62 fluoropyrimidine 62 Unresectable 62 Talabostat 62 mTOR mammalian target 62 Clolar ® 62 Interferon beta 1a 62 Reports Preclinical Data 62 AKT inhibitor 62 Achieves Primary Endpoint 62 Tyrosine Kinase Inhibitors 62 Therapeutic Efficacy 62 miconazole Lauriad ® 62 targeted radiotherapeutic 62 Hypercholesterolemia 62 Orphan Drug designations 62 busulfan 62 R bendamustine hydrochloride 62 Eluting Stent 62 myelofibrosis polycythemia vera 62 Cyclooxygenase 2 62 Secretory 62 mertansine 62 Antifungal 62 selective agonist 62 Romiplostim 62 Aplidin 62 IMiDs R 62 FS Antihemophilic Factor Recombinant 62 long acting muscarinic 62 Anthracycline 62 Janus Kinase 62 Orphan Status 62 Nephrol 62 Clinical Outcome 62 Mucosal 62 intranasal formulation 62 metastatic malignant 62 Initiates Phase 2b 62 methylnaltrexone bromide 62 P#X# antagonist 62 Fidaxomicin 62 Atypical Antipsychotic 62 cortisol synthesis 62 Non Responders 62 Adjuvant Therapy 62 Submits Supplemental 62 Tipranavir 62 Amrubicin 62 urate oxidase 62 paclitaxel poliglumex 62 Therapeutic Vaccine 62 ciprofloxacin hydrochloride 62 GVAX ® 62 Cutaneous T 62 Expanded Indication 62 tartrate Inhalation Solution 62 SinuNase ™ 62 Low Dose 62 familial amyloidotic polyneuropathy FAP 62 proteasome inhibitor 62 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 62 Adjunctive Therapy 62 octreotide acetate 62 Denufosol 62 IIa Clinical Trial 62 tazobactam 62 trastuzumab Herceptin R 62 DNA demethylating agent 62 Hepatitis C Virus HCV 62 Tumor Necrosis Factor 62 HCV RNA polymerase 62 Aldara ® 62 cMET 62 MKC# MKC# PP 62 ALN TTR 62 2 methoxyestradiol 62 cetuximab Erbitux R 61 dasatinib Sprycel 61 R brand levalbuterol 61 estramustine 61 Survival Benefit 61 Autologous Stem Cell Transplantation 61 oxaliplatin Eloxatin 61 Combination Treatment 61 SUTENT ® 61 Pharmacokinetic Study 61 pralatrexate injection folate analogue 61 Receives Milestone Payment 61 HCl capsules 61 Pivotal Trial 61 Unfractionated Heparin 61 protein kinase inhibitor 61 Treated Patients 61 Cancidas 61 acute peripheral arterial 61 bortezomib Velcade 61 KSP inhibitor 61 Soriatane R 61 Randomized Phase 61 uricase 61 Renal Function 61 Spectrum Pharmaceuticals Announces 61 cisplatin gemcitabine 61 Therapeutic Competitors Report 61 selectively binds 61 Significantly Reduces 61 Diabetic Foot Ulcer 61 activin receptor type 61 Diabetic Nephropathy 61 sapropterin dihydrochloride 61 JAK2 Inhibitor 61 immunostimulatory 61 successfully commercialize Iluvien 61 Sapacitabine 61 Gastrointestinal Stromal Tumors 61 Initiated Phase 61 Randomized Double Blind Placebo 61 Initiates Phase 61 denileukin diftitox 61 BCG refractory carcinoma 61 IMiD 61 Is Well Tolerated 61 muscarinic antagonist 61 Chronic Renal Failure 61 multikinase inhibitor 61 FDA Okays 61 Lymphoid 61 Enoxaparin 61 Miconazole 61 Sudhir Agrawal D.Phil 61 Tarceva TM 61 Febuxostat 61 Hematopoietic 61 HGS ETR1 mapatumumab 61 Lenocta TM 61 Oritavancin 61 Tambocor 61 alkylating agent 61 Tolerability 61 Phase III Trial 61 International SMI SYNN 61 PDE4 inhibitor 61 neutropenia thrombocytopenia 61 Breast Cancer Cells 61 Stimulon adjuvant 61 oral dihydropyrimidine dehydrogenase DPD 61 Phase IIa Clinical Trial 61 Contrast Agents 61 Dry Powder Inhalers 61 Medoxomil 61 Imatinib mesylate 61 PKC# 61 Antiarrhythmic 61 Skeletal Muscle 61 combines bupropion 61 xenograft models 61 Allergic Rhinitis 61 YONDELIS R 61 Radezolid 61 Trastuzumab DM1 61 Glycosylation 61 interferon gamma 1b 61 prasterone 61 Leukine ® 61 Progressive Multifocal Leukoencephalopathy 61 IMiDs ® compound 61 orally inhaled 61 anionic backbone 61 oral dual endothelin 61 Orphan Designation 61 antibody MAb 61 Azacitidine 61 Radiofrequency Ablation 61 recombinant FVIII 61 Dalbavancin 61 Investigational Agent 61 Toxoid 61 Previously Untreated 61 Anticoagulant 61 HER1 61 ALN HPN 61 Dapagliflozin 61 Pharmaceuticals Initiates 61 Anticancer Drug 61 BRILINTA 61 immunomodulating 61 INDUSTRY ASSESSMENTS 61 Antiviral Therapy 61 Presents Positive Preclinical 61 delafloxacin 61 Paraplatin ® 61 capsules USP 61 Irinotecan 61 cell lymphoma CTCL 61 Ribavirin causes 61 Announces FDA Clearance 61 Gliadel R 61 Infected Patients 61 Pegloticase 61 Granisetron 61 BioSante Pharmaceuticals Announces 61 telomerase therapeutic 61 K ras mutations 61 Hexvix ® 61 Begin Clinical Trials 61 Leukemias 61 VISICOL R 61 benign prostatic hypertrophy BPH 61 methicillin susceptible Staphylococcus aureus 61 Effectively Treats 61 Squamous 61 Ranolazine 61 Oral Cladribine 61 ZOLINZA 61 HuMax CD#b 61 peripherally acting 61 histone deacetylase inhibitor 61 Anticancer Activity 61 J Am Coll 61 fusidic acid 61 Tiotropium 61 Ofatumumab 61 Adjuvanted 61 Disease Progression 61 Topical Gel 61 Cholesterol Lowering Drug 61 Bezielle 61 PEGylated interferon beta 1a 61 Evoltra ® 61 Dose Ranging Study 61 Protein Kinase C 61 Hepatitis C Genotype 61 Treatment Naïve 61 Fluorouracil 61 Lubiprostone 61 Analogs 61 Upregulation 61 Streptococcus pyogenes 61 Initiate Phase III 61 HCV polymerase 61 ODT metoclopramide HCl PEPCID 61 Levaquin levofloxacin 61 NXL# 61 Preclinical Models 61 Randomised 61 Hepatitis B Virus 61 Oral Spray 61 Anthrax Toxin 61 Aplidin R 61 ISTODAX ® 61 liposomal doxorubicin 61 Nebulized 61 beta lactams 61 cromolyn sodium 61 Omacetaxine mepesuccinate 61 Lupus Drug 61 Taxol ® 61 Bucindolol 61 pharmacokinetic equivalence 61 Peginterferon Alfa 2b 61 DOXIL R 61 Ceragenin ™ 61 Balloon Catheters 61 Inhibitor 61 Clinical Efficacy 61 Begins Dosing 61 calcitonin gene related 61 Sumatriptan Succinate 61 Treating Chronic 61 FDA Orphan Drug 61 Potent Inhibitor 61 Remission Maintenance 61 Anticancer Agent 61 Oral Calcitonin 61 rxRNA 61 Dose Response 61 Statistically Significant 61 See CLINICAL PHARMACOLOGY 61 Staphylococcal 61 Myelodysplastic Syndrome MDS 61 Tocopherol 61 Chronic Myeloid Leukemia 61 include Alferon N 61 cytidine nucleoside analog 61 Signaling Pathway 61 Triamcinolone 61 Randomized Double blind 61 Demonstrates Sustained 61 TRAIL R1 61 Indomethacin 61 piperacillin tazobactam 61 Initiates Dosing 61 ribavirin Copegus 61 Preclinical Efficacy 61 Factor VIIa 61 synthetic siRNA 61 anti secretory 61 Aptivus ® 61 Benzyl 61 Gets FDA Clearance 61 Epirubicin 61 Patient Enrollment 61 Abstract Number 61 Darusentan 61 rilonacept 61 Terbinafine 61 included exfoliative dermatitis 61 Renal Cell Carcinoma 61 Taclonex R 61 generation purine nucleoside 61 ThermoDox R 61 Letairis ambrisentan 61 Neulasta R 61 Estrogen Receptor 61 nilotinib Tasigna 61 CCX# B 61 dihydrofolate reductase 61 Glucocorticoid 61 Submits Biologics License Application 61 Histone Deacetylase 61 Bevacizumab 61 Submits Response 61 Intravitreal 61 CG# [003] 61 Oropharyngeal Candidiasis 61 gets USFDA nod 61 Controlled Study 61 PRN FDA Approves 61 Immunoglobulin G 60 Investigational Drug 60 Castration Resistant Prostate Cancer 60 oropharyngeal candidiasis OPC 60 MGd 60 Phospholipase A2 60 Telbivudine 60 Saquinavir 60 Romidepsin 60 INVANZ 60 interferon inducible 60 Vaccine Candidate 60 Receptor Antagonists 60 Camptosar ® 60 Vaxfectin TM adjuvant 60 peptidic compound 60 Pulmonary Arterial Hypertension 60 virus HCV protease inhibitor 60 Appears Safe 60 Receptor Antagonist 60 Oral Formulation 60 NASH Huntington 60 imatinib resistant 60 GTC recombinant form 60 Mimetics 60 Entry Inhibitor 60 MEK inhibitors 60 Hepatocellular Carcinoma 60 Bioavailability 60 Patients Treated 60 LAB CGRP 60 Serostim ® 60 Am J Clin 60 Myelofibrosis 60 cyclophosphamide doxorubicin vincristine 60 hypertrichosis occurred 60 Genotyping Test 60 gefitinib Iressa 60 Newly Diagnosed Multiple Myeloma 60 favorable pharmacokinetic profile 60 antimitotic 60 Mylan Receives Approval 60 Prophylactic Treatment 60 pharmacodynamic profiles 60 Solzira ™ 60 Successfully Treated 60 Dose Finding 60 Chronic Sinusitis 60 novel synthetic peptide 60 Eraxis 60 Targeted Therapy 60 CYP #C# 60 Cypher Sirolimus 60 haematologic 60 III EGFRvIII 60 irinotecan doxorubicin oxaliplatin paclitaxel 60 receptor inhibitor 60 Dendritic Cells 60 CYP#A# isoenzyme 60 Cell Proliferation 60 refractory cutaneous T 60 alpha 2a 60 Septin9 biomarker 60 Palifosfamide 60 Telatinib 60 Atypical Hemolytic Uremic Syndrome 60 Crofelemer 60 Rigel R# 60 Oral Mucositis 60 Demonstrates Potential 60 Valopicitabine 60 Sandimmune 60 oral beclomethasone dipropionate 60 Microplasmin 60 Seasonal Allergic Rhinitis 60 progressive metastatic prostate 60 sorafenib Nexavar 60 COLAZAL R 60 HGS ETR2 60 vinca alkaloids 60 Genentech Rituxan 60 small molecule tyrosine 60 refractory metastatic 60 tetracycline antibiotic 60 Transfection 60 gemcitabine carboplatin 60 nasal decolonization 60 Water Soluble 60 Predict Response 60 Traficet EN 60 Aviptadil 60 systemic anaplastic large 60 RAV# 60 Alkeran 60 Transdermal Delivery 60 AMPA kainate 60 treat seborrheic dermatitis 60 erosive gastritis 60 norfloxacin 60 oral nucleoside analogue 60 Acute Ischemic Stroke 60 Antigenics QS 60 Inflammatory Markers 60 polyclonal 60 TM Drug Eluting 60 lyase 60 ADVIA Centaur XP 60 Glatiramer Acetate 60 tests miRview TM 60 Launches Generic Version 60 IMA# 60 Annexin A5 60 Patients Receiving 60 Saizen ® 60 Immunosuppressant 60 Akt inhibitor 60 Pediatric Patients 60 Janus kinase 60 Ondansetron Injection USP 60 TM Aganocide 60 Reovirus 60 papillary renal cell carcinoma 60 diclofenac sodium 60 Serostim R 60 CRMD# 60 Tanespimycin 60 paclitaxel Taxol 60 Inhalation Powder 60 novel topoisomerase 60 Late Breaker 60 5 fluorouracil leucovorin 60 P#Y# [001] 60 somatostatin 60 CIMZIA R